Aloxi Payment Cut By One-Third Under Medicare ASP Rule
Executive Summary
MGI's anti-emetic Aloxi is among the products that will see the steepest payment cuts when the Centers for Medicare & Medicaid Services implements average sales price-based reimbursement for drugs covered by Medicare Part B in 2005
You may also be interested in...
Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP
MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class
Aloxi Sees Share Gains, Volume Drop In First Month Under Medicare ASP
MGI Pharma's anti-emetic Aloxi (palonosetron) gained market share in the first month of average sales price-based reimbursement despite a drop in prescription volume for the class
Average Sales Prices Expected To Increase 3.4% From Proposed Rule
The Centers for Medicare & Medicaid Services expects that first quarter 2005 reimbursement rates for Medicare Part B drugs will reflect an increase of about 3.4% from those published in its proposed rule